World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
29097
World Ranking
14993
National Ranking
7578

Overview

Peter McLaughlin is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans a range of topics involving lymphoma diagnosis and treatment, cognitive neuroscience, and immune cell function. McLaughlin's work also touches on interdisciplinary areas including neuroethics, human enhancement, biomedical innovations, and coastal and marine dynamics.

The primary focus of McLaughlin's recent research includes lymphoma treatment strategies, as evidenced by their notable paper titled "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program", published in 2023 in the Journal of Clinical Oncology. This publication has been cited extensively and represents a significant contribution to the field of oncology.

McLaughlin frequently collaborates with a group of researchers, including Sundar Jagannath, Hagop M. Kantarjian, Sagar Lonial, Brad S. Kahl, and a coauthor identified as St Louis. Each of these colleagues shares ongoing professional ties and multiple joint publications.

The scientist has contributed to a range of publication venues, reflecting the interdisciplinary nature of their work. The most recurrent among these are:

  • Abstracts with programs - Geological Society of America
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Public Understanding of Science
  • Journal of Soils and Sediments

McLaughlin's subfields of study indicate a focus on:

  • Cognitive Neuroscience
  • Earth-Surface Processes
  • Philosophy
  • Pathology and Forensic Medicine
  • Oncology

Their research topics encompass:

  • Lymphoma Diagnosis and Treatment
  • Neural and Behavioral Psychology Studies
  • CAR-T Cell Therapy Research
  • Immune Cell Function and Interaction
  • Psychology of Moral and Emotional Judgment
  • Neuroethics, Human Enhancement, Biomedical Innovations
  • Coastal and Marine Dynamics

Some of the recent papers in the broader body of research associated with McLaughlin and their wider collaborative circle include:

  • "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program" (2023, Journal of Clinical Oncology)
  • "Neuroscience explanations really do satisfy: A systematic review and meta-analysis of the seductive allure of neuroscience" (2023, Public Understanding of Science)
  • "Monitoring the composition, authenticity and quality dynamics of commercially available Nigerian fat-filled milk powders under inclement conditions using NIRS, chemometrics, packaging and microbiological parameters" (2020, Food Chemistry)
  • "Impacts of unpaved roads on runoff and erosion in a dry tropical setting: Isla De Culebra, Puerto Rico" (2024, Journal of Soils and Sediments)
  • "Muscarinic M1, but not M4, receptor antagonism impairs divided attention in male rats" (2021, Pharmacology Biochemistry and Behavior)

Best Publications

  • Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

    P McLaughlin;A J Grillo-López;B K Link;R Levy

  • Follicular lymphoma international prognostic index.

    Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White

  • Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

    Thomas A. Davis;Antonio J. Grillo-López;Christine A. White;Peter McLaughlin

  • Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

    WS Velasquez;F Cabanillas;P Salvador;P McLaughlin

  • Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

    Massimo Federico;Monica Bellei;Luigi Marcheselli;Stefano Luminari

  • High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine

    Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio

  • Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

    N. L. Berinstein;A. J. Grillo-Lopez;C. A. White;I. Bence-Bruckler

  • Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro

  • ESHAP--an Effective Chemotherapy Regimen in Refractory and Relapsing Lymphoma: A 4-year Follow-Up Study

    W. S. Velasquez;P. McLaughlin;Susan L Tucker;Fredrick B Hagemeister

  • Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality

    Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee

  • Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.

    Issa F Khouri;Peter McLaughlin;Rima M Saliba;Chitra Hosing

  • Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma

    Koen van Besien;Chul S. Ha;Sandy Murphy;Peter McLaughlin

  • Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma.

    Peter McLaughlin;Fredrick B. Hagemeister;Jorge E. Romaguera;Andreas H. Sarris

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Richter's syndrome: a report on 39 patients.

    L. E. Robertson;William Pugh;Susan O'Brien;Hagop Kantarjian

  • Results of MIME salvage regimen for recurrent or refractory lymphoma

    Fernando Cabanillas;Fredrick B. Hagemeister;Peter McLaughlin;William S. Velasquez

  • Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: An uncontrolled trial

    Gideon Steinbach;Richard Ford;Gary Glober;Dory Sample

  • Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

    Jorge E. Romaguera;Luis E. Fayad;Lei Feng;Kimberly Hartig

  • Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

    Jorge E. Romaguera;L. Jeffrey Medeiros;Frederick B. Hagemeister;Luis E. Fayad

  • Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment

    Thomas A. Davis;Christine A. White;Peter McLaughlin;Myron S. Czuczman

Frequent Co-Authors

Fredrick B. Hagemeister
Fredrick B. Hagemeister The University of Texas MD Anderson Cancer Center
Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Fernando Cabanillas
Fernando Cabanillas The University of Texas MD Anderson Cancer Center
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Larry W. Kwak
Larry W. Kwak City Of Hope National Medical Center
Andre Goy
Andre Goy Hackensack University Medical Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Susan L. Tucker
Susan L. Tucker The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine doesn’t just mean becoming a doctor. There are numerous online degree options and career pathways in healthcare that offer strong job growth and rewarding opportunities.

For those interested in mental health, psych np programs provide an accelerated way to become a Psychiatric Mental Health Nurse Practitioner. This field allows you to make a direct impact on patients’ lives, and online programs offer both convenience and flexibility.

If you are more interested in the administrative side of healthcare, pursuing a healthcare administration degree cost can be a major factor in your decision. Comparing programs can help you find options that fit your budget without sacrificing quality.

For students seeking advanced leadership roles, the cheapest mha programs offer affordable pathways to a Master’s in Healthcare Administration, opening doors to executive positions in hospitals and clinics.

Finally, nurses looking to reach the top of their profession should consider the best dnp programs online. These Doctor of Nursing Practice degrees can be completed remotely, allowing nurses to continue working while advancing their careers.

Best Scientists Citing Peter McLaughlin

Trending Scientists